OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.

Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Publication Speed (median values for papers published in 2023): Submission to First Decision: 5.7 weeks; Submission to Acceptance: 17.9 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017

Special Issue

Health Modifiers of Neurocognitive Aging

Submission Deadline: November 30, 2018 (Open) Submit Now

Guest Editor

Kamen Tsvetanov, PhD

Centre for Speech, Language and the Brain, Department of Psychology, University of Cambridge, Downing Street, Cambridge CB2 3EB, UK

Website | E-Mail

Research Interests: Ageing; fMRI; neuroscience; connectomics; brain dynamics; cognitive neuroscience of ageing; relationship between human brain dynamics and cognition in healthy ageing and age-degenerative diseases

About This Topic

With the global demographic shift towards an older population, there is a pressing need to maintain mental wellbeing into late life, allowing people to work and live independently for longer. There are many influences on mental health which can be cultural, social, genetic, health and our own lifestyle decisions. These have an effect on our brain, and how well our brain works for what we call cognitive health – good memory, perception, language, judgement and so on.

The purpose of this Special Issue is to compile a number of selected research articles that focus on identifying factors for maintaining neurocognitive function across the lifespan – or ‘health modifiers’ – why some people seem to age without apparent adverse effects on their cognitive abilities, while others fare badly even without a dementia illness. In addition, this Special Issue welcomes review article submissions that critically assess the current knowledge on major health modifiers for mechanisms of neurocognitive aging. Addressing these issues has implications for understanding the influences that promote our brains process information to support mental functioning, throughout adult life.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (geriatrics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!


Open Access Perspective

Behavioural and Complementary Interventions for Healthy Neurocognitive Aging

Received: 30 November 2018;  Published: 20 March 2019;  doi: 10.21926/obm.geriatr.1901039


Background: While the percent of persons 65 and older is expected to increase to 17% of the world’s population by 2050, this increase in longevity does not necessarily suggest a parallel increase in health status. While aging is an inevitable aspect of living, there are factors which can accelerate morbidity and mortality, as well as factors [...]
Open Access Original Research

25-hydroxyvitamin D Levels are Associated with Cognitive Dysfunction in Type 2 Diabetes and the Metabolic Syndrome: A Preliminary Examination

Received: 01 August 2018;  Published: 05 December 2018;  doi: 10.21926/obm.geriatr.1804023


Background: Type 2 diabetes (T2DM) and metabolic syndrome are linked to pathological changes in the brain and increased likelihood of cognitive impairment. Vitamin D insufficiency is commonly found in this population and is associated with cognitive dysfunction in other patient groups. The present study aims to demonstrate the presence of [...]